Citadel Advisors
HELP

Citadel Advisors’s Helus Pharma Inc. Common Stock HELP Stock Holding History

Citadel Advisors’s Portfolio HELP Stock Details HELP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.1M Sell
620,959
-256,388
-29% -$1.28M ﹤0.01% 5081
2026
Q1 		$4.21M Buy
877,347
+71,970
+9% +$466K ﹤0.01% 4628
2025
Q4 		$6.59M Buy
805,377
+708,283
+729% +$4.56M ﹤0.01% 3861
2025
Q3 		$572K Buy
+97,094
New +$688K ﹤0.01% 8808
2025
Q2 		– Sell
-62,102
Closed -$452K – 12951
2025
Q1 		$394K Buy
+62,102
New +$538K ﹤0.01% 9000
2023
Q2 		– Sell
-9,857
Closed -$144K – 14457
2023
Q1 		$144K Buy
9,857
+6,612
+204% +$107K ﹤0.01% 10703
2022
Q4 		$36.6K Buy
+3,245
New +$53.5K ﹤0.01% 12515
2022
Q1 		– Sell
-1,407
Closed -$64K – 13732
2021
Q4 		$64K Sell
1,407
-130,835
-99% -$8.29M ﹤0.01% 13096
2021
Q3 		$11M Buy
+132,242
New +$11.6M ﹤0.01% 2915

Other funds holding HELP

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return

Citadel Advisors's HELP Position: Q2 2026 in Review

Citadel Advisors reduced its Helus Pharma Inc. Common Stock (HELP) stake by 29% in Q2 2026, selling an estimated $1.28M and leaving 620,959 shares worth $4.1M. The position accounts for ﹤0.01% of the portfolio, ranked #5081.

Citadel Advisors first reported a position in HELP in Q3 2021 and has held it in 9 quarters since. The position peaked at $11M in Q3 2021. 99 funds tracked by Wall St. Rank hold HELP as of Q2 2026.

  • Citadel Advisors held 620,959 shares of Helus Pharma Inc. Common Stock worth $4.1M as of Q2 2026.
  • Citadel Advisors sold 256,388 Helus Pharma Inc. Common Stock shares in Q2 2026, an estimated $1.28M.
  • Helus Pharma Inc. Common Stock made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #5081 holding.
  • Citadel Advisors first reported a position in Helus Pharma Inc. Common Stock in Q3 2021 and has held it in 9 quarters since.
  • Citadel Advisors's Helus Pharma Inc. Common Stock position peaked at $11M in Q3 2021.
  • 99 funds tracked by Wall St. Rank held Helus Pharma Inc. Common Stock as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.